Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Cablivi 10 mg powder and solvent for solution for injection

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Caplacizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Caplacizumab
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Cablivi contains the active substance caplacizumab. It is used to treat an episode of acquired thrombotic thrombocytopenic purpura in adults and adolescents of 12 years of age and older weighing at least 40 kg. This is a rare blood clotting disorder in which clots form in small blood vessels. These clots can block blood vessels and damage the brain, heart, kidneys, or other organs. Cablivi prevents the formation of these blood clots by stopping platelets in the blood from clumping together. By doing so, Cablivi reduces the risk of experiencing another episode of aTTP soon after the first.

Step 4 – Attaching the adapter

  • Take the packed vial adapter and remove the paper cover. Leave the adapter in its opened plastic packaging. Do not touch the adapter itself.
  • Place the adapter over the vial, while keeping the adapter in its plastic packaging.
  • Press down firmly until the adapter snaps into place, with the adapter spike going through the vial stopper. Leave the adapter attached to the vial, still in its outer packaging.

What you need to know before you take it

e Cablivi Do not use Cablivi

  • if you are allergic to caplacizumab or any of the other ingredients in this medicine (listed in section 6). Warnings and precautions Tell your doctor if you:
  • bleed excessively or experience unusual symptoms such as headache, shortness of breath, tiredness, or fainting which may indicate serious internal bleeding. Your doctor may ask you to stop the treatment. The doctor will say when you can start your treatment again.
  • are using medicines that prevent or treat blood clots such as warfarin, heparin, rivaroxaban, apixaban. Your doctor will decide how you should be treated.
  • are using anti-platelet agents such as aspirin, or low molecular weight heparin (which prevent blood clots). Your doctor will decide how you should be treated.
  • have a bleeding disorder such as haemophilia. Your doctor will decide how you should be treated.
  • have severely reduced liver function. Your doctor will decide how you should be treated.
  • are going to have an operation or dental treatment. Your doctor will decide if it can be postponed or if you should stop Cablivi before your surgery or dental treatment.

Step 5 – Prepare the syringe

  • Holding the syringe in your hand, break off the white cap with your other hand.
  • Do not use the syringe if this white cap is missing, loose or damaged.
  • Do not touch the syringe tip or allow it to come into contact with any surfaces.
  • Place the syringe on the clean flat surface. Step 6 – Connect syringe with adapter and vial
  • Take the vial with the attached adapter.
  • Remove the plastic packaging from the adapter by holding the vial with one hand, pressing the sides of the adapter packaging with your other hand, and then lifting the packaging upwards. Take care that the adapter does not come away from the vial.

Children and adolescents Cablivi is not recommended for children under 12 years and below 40 kg body weight. Other medicines and Cablivi Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. Also tell your doctor if you are using an anticoagulant medicine such as vitamin K antagonists, rivaroxaban, or apixaban which treat blood clots or anti-platelet agents, such as aspirin, or low molecular weight heparin which prevent blood clots.

  • Hold the adapter with the attached vial with one hand. Place the tip of the syringe on the connector part of the vial adapter.
  • Gently lock the syringe onto the vial by turning it clockwise until resistance is felt.

Pregnancy and breast-feeding Tell your doctor if you are pregnant or plan to get pregnant. Use of Cablivi is not recommended during pregnancy. Tell your doctor if you are breastfeeding. Your doctor will advise you whether to discontinue breastfeeding or not use Cablivi, considering the benefit of breastfeeding to the baby and the benefit of Cablivi to you. Driving and using machines Cablivi is not expected to influence the ability to drive or use machines. Cablivi contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'

Step 7 – Prepare the solution

  • Keep the vial standing vertically on the surface with the syringe pointing downwards.
  • Slowly push the syringe's plunger down until the syringe is empty. Do not remove the syringe from the vial.
  • With the syringe still connected to the vial adapter, gently swirl the vial with connected syringe until the powder is dissolved. Avoid foaming. Do not shake the vial.

How to take it

Cablivi Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Treatment with Cablivi is started by a doctor experienced in blood disorders. The recommended treatment is

  • first dose
  • 1 vial injected into a vein by a healthcare professional
  • the medicine will be given before starting plasma exchange.
  • subsequent doses
  • 1 vial once daily as a subcutaneous injection (under the skin of the belly)
  • the subcutaneous injection will be given after each daily plasma exchange
  • after the daily plasma exchange finishes, your treatment with Cablivi will continue for at least 30 days with injection of 1 vial once daily
  • your doctor may ask you to continue daily treatment until the underlying signs of your disease are resolved. Your doctor may decide that you or your caregiver may inject Cablivi. In this case, your doctor or healthcare provider will train you or your caregiver on how to use Cablivi. Instructions for use The first injection of Cablivi into your vein must be given by a healthcare professional. Instructions for healthcare professionals on how to inject Cablivi into your vein are at the end of the leaflet. For each injection, use a fresh kit package to prepare the injection solution. Do not try to inject Cablivi until you have been taught how to do so by a healthcare professional. Never use the kit for another injection. Step 1 – Cleaning
  • Wash your hands thoroughly with soap and water.
  • Prepare a clean flat surface for placing the kit package.
  • Make sure you have a disposal container at hand.
  • Allow the vial with connected syringe to stand on the surface for 5 minutes at room temperature to allow the solution to completely dissolve. The plunger may rise up by itself again – this is normal.
  • Go to step 8 immediately after these 5 minutes. Step 8 – Draw up solution
  • Check the solution for particles. All powder must be dissolved and the solution must be clear.
  • Slowly press the syringe's plunger fully down.
  • Turn the whole – vial, adapter and syringe – upside down.
  • While keeping it vertical, slowly pull the plunger to transfer all the solution into the syringe. Do not shake it.

Step 9 – Prepare the syringe for administration

  • Turn the whole – vial, adapter and syringe – rightside up (with the syringe at the top). Disconnect the filled syringe from the adapter by holding the adapter in one hand and gently turning the syringe counter-clockwise.
  • Put the vial and the attached adapter into the supplied disposal container.
  • Do not touch the syringe tip or allow it to touch the surface. Place the syringe on the clean flat surface.
  • Go to step 10 to inject caplacizumab under the skin of the belly. Instructions for healthcare professionals on how to inject Cablivi into your vein are at the end of the leaflet.

Step 10 – Attach the needle

  • Unpack the needle by tearing the paper cover off the needle packaging and removing the needle with protective cap.

Possible side effects

in a clinical study were reported with the following frequencies: Very common, may affect more than 1 in 10 people

  • bleeding gums
  • fever
  • tiredness
  • headache
  • nosebleeds
  • hives Common, may affect up to 1 in 10 people
  • bleeding from eye
  • vomiting blood
  • blood in the stools
  • black, tarry stools
  • bleeding from the stomach
  • bleeding haemorrhoids
  • rectal bleeding
  • injection site reactions: rash, itching and bleeding
  • bleeding in brain as evidenced by severe headache of rapid onset, vomiting, decreased level of consciousness, fever, sometimes seizures and neck stiffness or neck pain
  • muscle pain
  • stroke
  • blood in urine
  • excessive bleeding during periods
  • vaginal bleeding
  • coughing blood
  • shortness of breath
  • bruise Not known, frequency cannot be estimated from the available data
  • injection site pain, injection site bruising, redness around the injection site Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

The following information is intended for healthcare professionals only: The intravenous bolus injection of Cablivi given at the start of the treatment must be administered by a health care professional. Preparing a dose of Cablivi for intravenous injection should be done in the same way as for a subcutaneous injection (see Instructions for Use, step 1 to 9, in section 3). Cablivi can be intravenously administered by connecting the prepared syringe to standard Luer locks of intravenous lines or using a suitable needle. The line can be flushed with sodium chloride 9 mg/mL (0.9%) solution for injection.

How to store it

Cablivi Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in the original package in order to protect from light.

  • Without removing the needle cap, attach the needle to the syringe by turning clockwise until resistance is felt.
  • Pull back the needle safety shield.
  • Check the content of the syringe. Do not use the medicine if you see any cloudiness, clumps or anything else that looks abnormal. Contact your doctor or nurse if this happens. Step 11 – Prepare injection site for injection under the skin

Cablivi may be stored at a temperature not above 25 °C for a single period of up to 2 months, but not beyond the expiry date. Do not return Cablivi to refrigerated storage after storage at room temperature. Never expose to temperatures above 30 °C. Do not use Cablivi if you notice any particulate matter or discolouration prior to administration. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

  • Select a suitable place ('injection site') on your belly for injection under your skin. Avoid the area around the belly button. Select a different injection site from the one you used on the previous day to help the skin to recover after the injection.
  • Use the second alcohol pad to clean the injection site you have chosen. Step 12 – Administration
  • Carefully remove the needle protection cap from the needle and throw it away. Make sure the needle does not touch anything before the injection.
  • Hold the syringe at eye level with the needle pointing upwards.
  • Remove any air bubbles by tapping the side of the syringe with your finger to make the bubbles rise towards the tip. Then, slowly push the plunger until a small amount of liquid comes out of the needle.
  • Gently pinch the cleaned skin between your thumb and forefinger to make a fold.
  • Hold this skin fold during the entire injection.
  • Insert the full length of the needle into the skin fold at an angle as shown in the illustration.
  • Press the plunger down as far as it goes.
  • Pull out the needle at the same angle you inserted it. Do not rub the injection site. Step 13 – After administration
  • Immediately after the injection, move the needle safety shield over the needle, until it clicks into place.

What Cablivi contains

  • powder vial
  • The active substance is caplacizumab. Each vial contains 10 mg caplacizumab.
  • The other ingredients are sucrose, citric acid anhydrous, trisodium citrate dihydrate (see section 2 "Cablivi contains sodium") and polysorbate 80.
  • pre-filled syringe The pre-filled syringe contains 1 mL water for injections. What Cablivi looks like and contents of the pack Cablivi is provided as:
  • a white powder for solution for injection in a glass vial, and
  • water for injections in a pre-filled syringe to dissolve the powder. After dissolving the powder in the solvent, the solution is clear, colourless or slightly yellowish. Cablivi is available in
  • single packs each containing 1 vial with caplacizumab powder, 1 pre-filled syringe with solvent, 1 vial adapter, 1 needle and 2 alcohol swabs
  • multipacks each containing 7 single packs
  • multidose packs each containing 7 vials with caplacizumab powder, 7 pre-filled syringes with solvent, 7 vial adapters, 7 needles and 14 alcohol swabs. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Sanofi 410 Thames Valley Park Drive Reading Berkshire RG6 1PT UK Tel: 0800 035 2525 Email: [email protected] Manufacturer Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist. This leaflet was last revised in April 2026.
  • Put the syringe with the needle in a disposal container. If you use more Cablivi than you should An overdose is unlikely since one vial contains only a single dose. Tell your doctor if you think you have had an overdose. If you forget to use Cablivi If you miss a dose you should still take it if it is within 12 hours of the scheduled time. If more than 12 hours have passed since the dose should have been given, do not take the missed dose, but inject the next dose at the usual time. If you stop using Cablivi To get the most benefit from your treatment, it is important to use Cablivi as prescribed and for as long as your doctor tells you to use it. Please talk to your doctor before you stop the treatment because stopping it too early can cause your condition to come back. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor immediately if any of the following serious side effects occur: Long or excessive bleeding. Your doctor may decide to keep you under closer observation or change your treatment.

Frequently asked questions about Cablivi 10 mg powder and solvent for solution for injection

How do I take Cablivi 10 mg powder and solvent for solution for injection?

Cablivi 10 mg powder and solvent for solution for injection comes as injection containing 10mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Cablivi 10 mg powder and solvent for solution for injection?

The active substance in Cablivi 10 mg powder and solvent for solution for injection is caplacizumab.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Cablivi 10 mg powder and solvent for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Cablivi 10 mg powder and solvent for solution for injection without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Caplacizumab (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Cablivi is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

4.2. Posology and method of administration

Treatment with Cablivi should be initiated and supervised by physicians experienced in the management of patients with thrombotic microangiopathies.

Posology

First dose

Intravenous injection of 10 mg of caplacizumab prior to plasma exchange.

Subsequent doses

Daily subcutaneous administration of 10 mg of caplacizumab after completion of each plasma exchange for the duration of daily plasma exchange treatment, followed by daily subcutaneous injection of 10 mg of caplacizumab for 30 days after stopping daily plasma exchange treatment.

If at the end of this period there is evidence of unresolved immunological disease, it is recommended to optimise the immunosuppression regimen and continue daily subcutaneous administration of 10 mg of caplacizumab until the signs of underlying immunological disease are resolved (e.g. sustained normalisation of ADAMTS13 activity level).

In the clinical development program, caplacizumab has been administered daily for up to 71 days consecutively. Data on re-treatment with caplacizumab are available (see section 5.1).

Missed dose

The first dose of caplacizumab should be administered intravenously before the initial plasma exchange. If the administration of the first intravenous dose of caplacizumab is missed and plasma exchange is already administered, the first caplacizumab dose should still be administered intravenously after the plasma exchange is complete and the next dose should be administered subcutaneously on the following day according to the usual dosing schedule.

If a dose of Cablivi is missed, it can be administered within 12 hours. If more than 12 hours have passed since the dose was to have been given, the missed dose should NOT be administered and the next dose should be administered per the usual dosing schedule.

Special populations

Renal impairment

No dose adjustment is necessary for patients with renal impairment (see section 5.2).

Hepatic impairment

No dose adjustment is necessary for patients with hepatic impairment (see section 5.2). See section 4.4 for special considerations in patients with severe hepatic impairment.

Elderly

While experience with the use of caplacizumab in the elderly is limited, there is no evidence to suggest that dose adjustment or special precautions are needed for elderly patients (see section 5.2).

Paediatric population

The safety and efficacy of caplacizumab in the paediatric population have not been established in clinical studies. The posology of Cablivi in adolescents of 12 years of age and older weighing at least 40 kg is the same as in adults (see section 5.2). No recommendations can be made on the posology of Cablivi for paediatric patients below 40 kg of body weight.

Method of administration

The first dose of Cablivi is to be administered as an intravenous injection. Subsequent doses are to be administered via subcutaneous injection in the abdomen.

Injections into the area around the navel should be avoided and consecutive injections should not be administered in the same abdominal quadrant.

Patients or caregivers may inject the medicinal product after proper training in the subcutaneous injection technique.

For instructions on reconstitution of Cablivi before administration, see section 6.6.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Bleeding

Cablivi increases the risk of bleeding. Cases of major bleeding, including life-threatening and fatal bleeding have been reported in patients receiving caplacizumab, mainly in those using concomitant anti-platelet agents or anticoagulants. Caplacizumab should be used with caution in patients with underlying conditions that may predispose them to a higher risk of bleeding.

In case of clinically significant bleeding, treatment with Cablivi should be interrupted. If needed, the use of von Willebrand Factor concentrate could be considered to correct haemostasis. Cablivi should only be restarted upon the advice of a physician experienced in the management of thrombotic microangiopathies. If Cablivi is restarted, monitor closely for signs of bleeding.

In the setting of concomitant use of oral anticoagulants, anti-platelet agents, thrombolytic agents or heparin

The risk of bleeding is increased with concomitant use of Cablivi with other medicinal products affecting haemostasis and coagulation. Initiation or continuation of treatment with oral anticoagulants (e.g., vitamin K antagonists or direct oral anticoagulants [DOAC] such as thrombin inhibitors or factor Xa inhibitors), anti-platelet agents, thrombolytic agents such as urokinase, tissue plasminogen activator (t-PA) (e.g. alteplase) or heparin requires careful consideration and close clinical monitoring.

In patients with coagulopathies

Due to a potential increased risk of bleeding, use of Cablivi in patients with underlying coagulopathies (e.g. haemophilia, other coagulation factor deficiencies) must be accompanied by close clinical monitoring.

In patients undergoing surgery

If a patient is to undergo elective surgery, an invasive dental procedure or other invasive interventions, the patient must be advised to inform the physician or dentist that they are using caplacizumab and it is recommended to withhold treatment for at least 7 days before the planned intervention. The patient must also notify the physician who supervises the treatment with caplacizumab about the planned procedure. After the risk of surgical bleeding has resolved, and caplacizumab is resumed, the patient should be monitored closely for signs of bleeding.

If emergency surgery is needed, the use of von Willebrand Factor concentrate is recommended to correct haemostasis.

Severe hepatic impairment

No formal study with caplacizumab has been conducted in patients with severe acute or chronic hepatic impairment and no data regarding the use of caplacizumab in these populations are available. Use of Cablivi in this population requires a benefit/risk assessment and close clinical monitoring.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies evaluating use of caplacizumab with oral anticoagulants (e.g. vitamin K antagonists, direct oral anticoagulants [DOAC] such as thrombin inhibitors or factor Xa inhibitors), antiplatelet agents, thrombolytic agents such as urokinase, tPA (e.g. alteplase) or heparin have been performed (see section 4.4 In the setting of concomitant use of oral anticoagulants, anti-platelet agents, thrombolytic agents or heparin).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no data on the use of caplacizumab in pregnant women. Studies in guinea pigs showed no effect of caplacizumab on the dams or foetuses (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Cablivi during pregnancy.

Breastfeeding

There are no data on the use of caplacizumab in breastfeeding women. It is unknown whether caplacizumab is excreted in human milk. A risk to the child cannot be excluded.

A decision must be made whether to discontinue breastfeeding or to abstain/discontinue from therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

Fertility

The effects of caplacizumab on fertility in humans are unknown. In animal toxicology studies, no impact of caplacizumab on male and female fertility parameters was observed (see section 5.3).

4.7. Effects on ability to drive and use machines

Cablivi has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profile

The most frequent adverse reactions in the TITAN and HERCULES clinical studies were epistaxis, headache and gingival bleeding. The most common serious adverse reaction was epistaxis.

Tabulated list of adverse reactions

Adverse reactions are listed below by MedDRA system organ class and by frequency. Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).

Table 1 . List of adverse reactions in TITAN and HERCULES studies

MedDRA System organ class

Very common

Common

Nervous system disorders

Headache

Cerebral infarction

Eye disorders

Eye Haemorrhage*

Vascular disorders

Haematoma*

Respiratory, thoracic and mediastinal disorders

Epistaxis*

Dyspnoea, Haemoptysis*

Gastrointestinal disorders

Gingival bleeding*

Haematemesis*, haematochezia*, melaena*, upper gastrointestinal haemorrhage*, haemorrhoidal haemorrhage*, rectal haemorrhage *, abdominal wall haematoma*

Skin and subcutaneous tissue disorders

Urticaria

Musculoskeletal and connective tissue disorders

Myalgia

Renal and urinary disorders

Haematuria*

Reproductive system and breast disorders

Menorrhagia*, vaginal haemorrhage*

General disorders and administration site conditions

Pyrexia, Fatigue

Injection site haemorrhage*, injection site pruritus, injection site erythema, injection site reaction±

Injury, poisoning and procedural complications

Subarachnoid haemorrhage*

*Bleeding events: see below

±In post-marketing experience, this also includes injection site pain and injection site bruising

Description of selected adverse reactions

Bleeding

In clinical studies, bleeding events occurred in different body systems, independent of treatment duration. In the postmarketing setting, cases of major bleeding, including life-threatening and fatal bleeding have been reported in patients receiving caplacizumab, mainly in those using concomitant anti-platelet agents or anticoagulants. In case of clinically significant bleeding, consider actions outlined in sections 4.4 and 4.9.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

In case of overdose, based on the pharmacological action of caplacizumab, there is the potential for an increased risk of bleeding. Close monitoring for signs and symptoms of bleeding is recommended. (see section 4.4).

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • CABLIVI 10 mg prescriptionCAPLACIZUMABUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • CabliviCaplacizumabum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Cablivi 10 mg powder and solvent for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →